Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP - Lu, Min; Breyssens, Hilde; Salter, Victoria; Zhong, Shan; Hu, Ying; Baer, Caroline; Ratnayaka, Indrika; Sullivan, Alex; Brown, Nicholas R.; Endicott, Jane; Knapp, Stefan; Kessler, Benedikt M.; et al. (Cancer cell, 2013)
Keywords: Active Transport, Cell Nucleus - drug effects; Animals; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; CDC2 Protein Kinase - genetics; CDC2 Protein Kinase - metabolism; CDC2 Protein Kinase - physiology; Cell Line, Tumor; Cell Nucleus - metabolism; Cell Proliferation - drug effects; Cyclin B1 - genetics; Cyclin B1 - metabolism; Cyclin B1 - physiology; Dimerization; Humans; Imidazoles - pharmacology; Indoles - pharmacology; Intracellular Signaling Peptides and Proteins - analysis; Intracellular Signaling Peptides and Proteins - metabolism; M Phase Cell Cycle Checkpoints; Melanoma - genetics; Melanoma - metabolism; Melanoma - pathology; Mice; Neoplasm Metastasis; Nocodazole - pharmacology; Phosphorylation - drug effects; Piperazines - pharmacology; Proto-Oncogene Proteins c-mdm2 - analysis; Proto-Oncogene Proteins c-mdm2 - metabolism; Repressor Proteins - analysis; Repressor Proteins - metabolism; Sulfonamides - pharmacology; Triazoles - pharmacology; Tumor Suppressor Protein p53 - physiology; Vemurafenib; Xenograft Model Antitumor Assays